HLX02: Innovation Could Overtake
The oncology treatment landscape in China is evolving rapidly as the government has prioritized access to innovative drugs to meet this significant...
496 Views
Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
Corrigenda: There is an error in this insight, please note the correction. Correction: The drug name Conbercept has been misspelt as...
863 Views
Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)
In our last Insight covering Ascletis Pharma (Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market ), we discuss the...
549 Views
Smartkarma: ECM Coverage Weekly Update (23 September 2017)
The Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. This week we see...
206 Views
Best Inc Reduces IPO Deal Size, Cuts Pricing, Then Settles for Just US$10 Per ADS
After reducing the size of its offering and slashing the price range for its ADSs on Tuesday morning, Best Inc reportedly priced its shares at just...
236 Views